Figitumumab Not Safe or Effective for Advanced Non-Adenocarcinoma Non-Small Cell Lung Cancer (NSCLC)

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the journal Annals of Oncology, researchers have found that the addition of figitumumab to erlotinib did not improve overall survival in patients with advanced, non-adenocarcinoma non-small cell lung cancer (NSCLC) who have received prior therapy.

For the multicenter, open-label, phase 3 study, 583 patients with stage 3B/4 non-adenocarcinoma NSCLC or recurrent disease with non-adenocarcinoma histology who had previously received at least one platinum-based therapy were randomly assigned to receive erlotinib 150mg daily with or without figitumumab 20mg/kg.

The study was stopped early by an independent data safety monitoring committee due to nine treatment-related deaths, specifically three related to both drugs, four attributed to erlotinib alone, and two related to figitumumab.

Results showed a median overall survival of 5.7 months for the combination group compared with 6.2 months for the erlotinib alone group (HR = 1.09, 95% CI: 0.91 - 1.31; P = 0.35). Median progression-free survival was 2.1 months and 2.6 months for the combination group and erlotinib alone group, respectively (HR = 1.08, 95% CI: 0.90 - 1.29; P = 0.43).

As a result of the safety concerns and the early study closure, the clinical development of figitumumab has been discontinued.

Figitumumab Not Safe or Effective for Advanced Non-Adenocarcinoma Non-Small Cell Lung Cancer (NSCLC)
Figitumumab to erlotinib did not improve overall survival in non-small cell lung cancer (NSCLC).
This multicenter, randomized, phase III study investigated the efficacy of figitumumab plus erlotinib compared with erlotinib alone in patients with pretreated, non–small cell lung cancer (NSCLC).

The addition of figitumumab to erlotinib did not improve OS in patients with advanced, pretreated, non–adenocarcinoma NSCLC. Clinical development of figitumumab has been discontinued.

READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs